A Meta-Analysis of Gene Silencer Therapy in ATTR-CM

30 August 2026 (14:30 - 14:45)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Doctor Julian Gillmore

UCL, Greater London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

A Phase 3 Clinical Trial of I124-evuzamitide to Diagnose Cardiac Amyloidosis

Doctor S. Dorbala (Boston, US)

Presentation thumbnail

Efficacy and safety of transthyretin gene silencer eplontersen in patients with transthyretin amyloid cardiomyopathy receiving stabiliser therapy in the CARDIO-TTRansform trial

Doctor P. Garcia-Pavia (Majadahonda, ES)

Presentation thumbnail

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy

Doctor Y. Hamatani (Boston, US)

Presentation thumbnail

Effect of anselamimab on cardiac structure and function in patients with light chain amyloidosis: The CARES trials

Doctor X. Wang (Boston, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

30 August 2026 14:30 CET

You may be interested in

Congress Presentation

Transthyretin gene silencing therapy in Val50Met familial amyloid polyneuropathy with associated cardiomyopathy

11 May 2026

Congress Session

Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments

17 May 2025

Congress Session

Clinical and real-world data in ATTR cardiomyopathy: reviewing their place in daily practice

19 May 2025

Congress Presentation

Cardiac MRI as a possible alternative to echocardiography for therapeutic response monitoring in ATTR cardiomyopathy: a multiparametric evaluation in patisiran treated patients

11 May 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources